Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
- 1 October 2020
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (10) , 1195-1202.e2
Abstract
No abstract availableKeywords
Funding Information
- Health and Family Planning Commission of Heilongjiang Province (2017-036)
- National Institute for Health and Care Research
- University of Birmingham
- National Natural Science Foundation of China (H2501)
This publication has 27 references indexed in Scilit:
- Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial FibrillationThe American Journal of Medicine, 2018
- Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App TrialThe American Journal of Medicine, 2017
- Bleeding Risk Scores in Atrial Fibrillation and Venous ThromboembolismThe American Journal of Cardiology, 2017
- The ABC pathway: an integrated approach to improve AF managementNature Reviews Cardiology, 2017
- Stroke prevention in atrial fibrillation: Past, present and futureThrombosis and Haemostasis, 2017
- Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation ProjectScientific Reports, 2016
- Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scoresJournal of Thrombosis and Haemostasis, 2016
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Net Clinical Benefit of Warfarin in Patients With Atrial FibrillationCirculation, 2012
- A Method to Determine the Optimal Intensity of Oral Anticoagulant TherapyThrombosis and Haemostasis, 1993